Norway PHARMAQ and the Norwegian School of Veterinary Science have identified the virus causing cardiomyopathy syndrome (CMS) of Atlantic salmon. Through this discovery more tools will become available that will make it possible to control the disease and limit the spread and the impact of the disease. PHARMAQ will explore the possibilities for developing a vaccine against CMS, a disease which currently results in significant losses for the aquaculture industry.
Cardiomyopathy syndrome of Atlantic salmon was first recorded in the mid 80’s in Norway. Economic losses are high since primarily fish at slaughter size die. The virus was discovered through a close research collaboration between PHARMAQ with project manager Marit Rode, and Professor Øystein Evensen and his research group at the Norwegian School of Veterinary Science. This is a result of a close and productive collaboration over many years, say the two scientists. The research program was partly funded by the Research Council of Norway. Read more ...
This blog is written by Martin Little The Aquaculturists, published and supported by the International Aquafeed Magazine from Perendale Publishers
Cardiomyopathy syndrome of Atlantic salmon was first recorded in the mid 80’s in Norway. Economic losses are high since primarily fish at slaughter size die. The virus was discovered through a close research collaboration between PHARMAQ with project manager Marit Rode, and Professor Øystein Evensen and his research group at the Norwegian School of Veterinary Science. This is a result of a close and productive collaboration over many years, say the two scientists. The research program was partly funded by the Research Council of Norway. Read more ...
This blog is written by Martin Little The Aquaculturists, published and supported by the International Aquafeed Magazine from Perendale Publishers
No comments:
Post a Comment